{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:48Z","timestamp":1789056408920,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011918","name":"Hemophilia of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201780","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:43:45Z","timestamp":1781225025000},"page":"201780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Jennifer","family":"Okalova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna M.","family":"Branella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barichello de Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Hunter","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Doering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-2202","authenticated-orcid":false,"given":"H. Trent","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201780_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13238-019-0633-0","article-title":"New paradigms on hematopoietic stem cell differentiation","volume":"11","author":"Cheng","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.omta.2026.201780_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","article-title":"Haematopoietic stem cell activity and interactions with the niche","volume":"20","author":"Pinho","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201780_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.705410","article-title":"The Hematopoietic Bone Marrow Niche Ecosystem","volume":"9","author":"Fr\u00f6bel","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omta.2026.201780_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.immuni.2018.03.024","article-title":"Niches for Hematopoietic Stem Cells and Their Progeny","volume":"48","author":"Wei","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.omta.2026.201780_bib5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.omta.2026.201780_bib6","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2007-04-082602","article-title":"Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens","volume":"110","author":"Ide","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/gt.2012.76","article-title":"Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A","volume":"20","author":"Johnston","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201780_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201780_bib9","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201780_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201780_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201780_bib12","first-page":"3566","article-title":"In vivo depletion of hematopoietic stem cells in the rat by an anti-CD45 (RT7) antibody","volume":"99","author":"Dahlke","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.omta.2026.201780_bib13","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2002-08-2379","article-title":"Anti-CD45\u2013mediated cytoreduction to facilitate allogeneic stem cell transplantation","volume":"101","author":"Wulf","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201780_bib15","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2014-02-550327","article-title":"In utero depletion of fetal hematopoietic stem cells improves engraftment after neonatal transplantation in mice","volume":"124","author":"Derderian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201780_bib18","doi-asserted-by":"crossref","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201780_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood-2015-12-689083","article-title":"KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice","volume":"129","author":"Chandrakasan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ymthe.2018.03.003","article-title":"Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment","volume":"26","author":"Arai","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201780_bib21","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib22","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.stem.2019.05.018","article-title":"Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance","volume":"25","author":"George","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omta.2026.201780_bib24","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201780_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201780_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41467-018-08202-w","article-title":"Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201780_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.omtm.2020.02.001","article-title":"Effective multi-lineage engraftment in a mouse model of Fanconi anemia using non-genotoxic antibody-based conditioning","volume":"17","author":"Srikanthan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Develop."},{"key":"10.1016\/j.omta.2026.201780_bib28","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/bloodadvances.2020003841","article-title":"5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice","volume":"5","author":"Bankova","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201780_bib29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.omtm.2021.04.016","article-title":"Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII","volume":"21","author":"Russell","year":"2021","journal-title":"Mol. Ther Methods Clin. Develop."},{"key":"10.1016\/j.omta.2026.201780_bib30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-021-00283-5","article-title":"Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells","volume":"29","author":"Zoine","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201780_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201780_bib33","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201780_bib34","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1038\/s41467-025-60464-3","article-title":"A non-genotoxic stem cell therapy boosts lymphopoiesis and averts age-related blood diseases in mice","volume":"16","author":"Konturek-Ciesla","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201780_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair","volume":"135","author":"Wilson","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201780_bib36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omta.2026.201780_bib37","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00204-021-03092-2","article-title":"New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids","volume":"95","author":"Rodrigues","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.omta.2026.201780_bib38","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omta.2026.201780_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab032","article-title":"A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate","volume":"3","author":"Chalabi-Dchar","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omta.2026.201780_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/7651_2016_361","article-title":"Analysis of Cell Cycle Status of Murine Hematopoietic Stem Cells","volume":"1516","author":"Szade","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201780_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13287-016-0311-6","article-title":"Delineating the effects of 5-fluorouracil and follicle-stimulating hormone on mouse bone marrow stem\/progenitor cells","volume":"7","author":"Shaikh","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.omta.2026.201780_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omta.2026.201780_bib43","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.1038\/s41598-018-27425-x","article-title":"Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice","volume":"8","author":"Pievani","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201780_bib44","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib45","first-page":"100","article-title":"Characterization of the immune response to factor VIII using hemophilia A\u2217 mice","volume":"85","author":"Hoyer","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.omta.2026.201780_bib46","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0037-1614124","article-title":"Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A","volume":"84","author":"Reipert","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201780_bib47","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/s-0037-1613094","article-title":"Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII","volume":"87","author":"Hausl","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201780_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0037-1612983","article-title":"Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII","volume":"87","author":"Sasgary","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201780_bib49","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","article-title":"Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation","volume":"110","author":"Meeks","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib50","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2012-09-456582","article-title":"The diversity of the immune response to the A2 domain of human factor VIII","volume":"121","author":"Markovitz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880829","article-title":"Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway","volume":"13","author":"Patel","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201780_bib52","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201780_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ regulatory T cells","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201780_bib54","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201780_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cmi.2015.92","article-title":"Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment","volume":"14","author":"Jin","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omta.2026.201780_bib56","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.omtm.2020.05.001","article-title":"Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates","volume":"17","author":"Samelson-Jones","year":"2020","journal-title":"Mol. Ther. Methods Clin. Develop."},{"key":"10.1016\/j.omta.2026.201780_bib57","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201780_bib58","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.22930","article-title":"Blocking of experimental arthritis by cleavage of IgG antibodies in vivo","volume":"56","author":"Nandakumar","year":"2007","journal-title":"Arthritis Rheum.: Off. J. Am. College Rheumatol."},{"key":"10.1016\/j.omta.2026.201780_bib59","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.2019000437","article-title":"Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia","volume":"133","author":"Kizlik-Masson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omta.2026.201780_bib61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-59745-237-3_13","article-title":"Transduction of murine hematopoietic stem cells and in vivo selection of gene-modified cells","volume":"433","author":"Ide","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201780_bib62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2003-05-1558","article-title":"Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment","volume":"103","author":"Mazurier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201780_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0301-472X(00)00610-X","article-title":"Ex vivo expansion of hematopoietic progenitor cells and mature cells","volume":"29","author":"McNiece","year":"2001","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omta.2026.201780_bib64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni0402-314","article-title":"Hematopoietic stem cells for transplantation","volume":"3","author":"Verfaillie","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omta.2026.201780_bib65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201780_bib66","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201780_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","article-title":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","volume":"317","author":"Huijbers","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omta.2026.201780_bib68","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"R\u00edo","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201780_bib69","doi-asserted-by":"crossref","first-page":"164.e1","DOI":"10.1016\/j.jtct.2022.08.015","article-title":"Non-genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia","volume":"29","author":"Chan","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omta.2026.201780_bib70","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jth.13202","article-title":"Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene","volume":"14","author":"Chao","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.omta.2026.201780_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pep.2007.11.005","article-title":"Expression and purification of cysteine introduced recombinant saporin","volume":"58","author":"G\u00fcnhan","year":"2008","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.omta.2026.201780_bib72","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/blood-2005-12-4961","article-title":"High-level expression of porcine factor VIII from genetically modified bone marrow\u2013derived stem cells","volume":"107","author":"Gangadharan","year":"2006","journal-title":"Blood"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:13:21Z","timestamp":1789053201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001151"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201780","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201780"}}